Dernières nouvelles pour Fox (NASDAQ:FOX) Stock

Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay-TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay-TV bundle. The Murdoch family controls Fox.

Fox Corp

Shapeshift FOX Token - United States Dollar

Fox Factory Holding Corp

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

Foxx Development Holdings Inc. - Common Stock

Foxx Development Holdings Inc

FOXY - United States Dollar

WIIM

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8M public offering.

News

Guidance

Sciencejoy Holding Sees Q4 Net Revenues RMB300-RMB330M

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $9 to $7.

Price Target

Analyst Ratings

RMTI

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $7

Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/BBY/earnings">opening bell on Tuesday, Nov. 26</a>.
Analysts expect the Richfield, Minnesota-based bank to report quarterly earnings at $1.29 per share, compared to $1.29 per share in the year-ago period. Best Buy projects to report revenue of $9.63 billion for the recent quarter, compared to $9.76 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Friday, JPMorgan maintained an Overweight rating on the stock and raised its price target from $111 to $117.
With the recent buzz around Best Buy, some investors may be eyeing potential gains from the company's dividends, too. As of now, Best Buy offers an annual dividend yield of 4.20%. That&#8217;s a quarterly dividend of 94 cents per share ($3.76 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $142,906 or around 1,596 shares. For a more modest $100 per month or $1,200 per year, you would need $28,563 or around 319 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.76 in this case). So, $6,000 / $3.76 = 1,596 ($500 per month), and $1,200 / $3.76 = 319 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
BBY Price Action: Shares of Best Buy gained 3.5% to close at $89.54 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Best Buy Stock Ahead Of Q3 Earnings

Sciencejoy Holding Nine Months Ending Sept. 30 EPS RMB1.03 Up From RMB(0.86) YoY; Revenue RMB1.012B Down From RMB1.036B YoY

Contracts

KULR

KULR Announces US Navy Contract For High-Temperature Internal Short Circuit Cells, Terms Not Disclosed

The earnings results for Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) for Q3 were made public on Monday, November 25, 2024 at 07:30 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Alarum Technologies beat estimated earnings by 400.0%, reporting an EPS of $0.2 versus an estimate of $0.04.
Revenue was up $450 thousand from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.1 in the previous quarter, leading to a 9.0% drop share price change the next day.
Here's a look at Alarum Technologies's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.31</td>
<td>0.28</td>
<td>0.25</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.41</td>
<td>0.23</td>
<td>0.30</td>
<td>0.03</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.94M</td>
<td>7.38M</td>
<td>7.00M</td>
<td>6.60M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.88M</td>
<td>8.38M</td>
<td>7.11M</td>
<td>6.75M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Alarum Technologies <a href="https://www.benzinga.com/quote/ALAR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

Insights into Alarum Technologies Q3 Earnings

Portugal-based medical marijuana grower Gro-Vida teamed up with Canopy Growth Germany GmbH, a subsidiary of cannabis giant Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>). This agreement is a key step for Gro-Vida to position itself in Germany&#8217;s growing medical marijuana market while supporting Canopy Growth GmbH&#8217;s strategy of securing EU-based supply through an asset-light approach in addition to existing supply from the company's Canadian GMP production platform.
"We are incredibly proud to be working with Canopy Growth Germany," stated Mallory Bodnar, managing director at Gro-Vida. "It is a remarkable honor to have a global leader recognize the exceptional quality of cannabis produced here in Portugal. This is not only a testament to our hard work but points to the promising future of Portuguese-grown cannabis on the world stage."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41997646/tilray-joins-german-cannabis-fiesta-with-first-locally-grown-strains">Tilray Joins German Cannabis Fiesta With First Locally Grown Strains</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
The supply agreement represents an opportunity to drive growth for both companies, blending Gro-Vida's cultivation expertise and EU-GMP production partnerships with Canopy Growth GmbH's extensive network and in-market expertise. Under the terms of the supply agreement, Gro-Vida will cultivate a range of exclusive medicinal cannabis flower for Canopy Growth GmbH, with the products slated for release under the Tweed brand.
<a href="https://www.benzinga.com/markets/cannabis/23/05/32592244/motherhood-brought-her-to-marijuana-now-shes-in-a-c-suite-at-a-global-weed-brand">Tara Rozalowsky</a>, chief growth officer and president, International, Canopy Growth, says this move is part of the company's larger plans for international expansion. "Part of our global strategy is ensuring a diverse and high-quality supply chain, and Gro-Vida is an important piece of this strategy. Sourcing EU-GMP flower from Portugal, alongside our EU-GMP Canadian-grown cannabis flower, allows us to offer a versatile and competitive product portfolio in the German market while advancing our asset light strategy for growth."
Products will be available via prescription and can be requested by patients nationwide in Germany from their healthcare practitioner beginning in calendar Q1 of 2025.
<h2 class="wp-block-heading">Cannabis In Germany</h2>
A recent <a href="https://prohibitionpartners.com/reports/the-german-cannabis-report/" target="_blank" rel="noreferrer noopener">report</a> on Germany&#8217;s cannabis market by Prohibition Partners revealed that German medical marijuana sales are projected to reach €420 million in 2024 ($260.66 million) reaching €1 billion by 2028.
The report comes several months after major cannabis reform in Germany with the implementation of the Cannabis Act (CanG) and the associated MedCanG Act. Partial cannabis legalization <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" target="_blank" rel="noreferrer noopener">took effect in Germany on April 1</a>, allowing people over 18 to legally possess up to 25 grams of dried cannabis and cultivate up to three plants at home. One of the biggest breakthroughs under the law is that medical cannabis is essentially <a href="https://www.benzinga.com/markets/cannabis/24/07/39830117/medical-marijuana-regulated-as-ibuprofen-is-one-of-the-biggest-breakthroughs-of-germanys-cannabi" target="_blank" rel="noreferrer noopener">regulated like ibuprofen</a>.
<h2 class="wp-block-heading">Price Action</h2>
Canopy Growth shares closed Friday's market session 1.04% higher at $3.9 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/11/42126680/german-cannabis-20-tons-10m-grams-and-thats-only-0-3-of-the-market-whats-missing">German Cannabis: 20 Tons, 10M Grams &#8211; And That&#8217;s Only 0.3% Of The Market, What&#8217;s Missing?</a></li>
</ul>

Photo: Courtesy of OMfotovideocontent on Shutterstock

Cannabis

Eurozone

Canopy Growth's German Subsidiary Teams Up With Portugal's Gro-Vida To Expand Medical Cannabis Supply

<ul>
<li>Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS
<ul>
<li>New pre-clinical data from the Company's Nav1.1 program</li>
</ul>
</li>
</ul>

Biotech

Events

General

XENE

Xenon To Present Long-Term Azetukalner Data At AES 2024

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Shares of Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) fell sharply in today's pre-market trading after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer&#8217;s disease in the ReThink-ALZ <a href="https://www.benzinga.com/quote/SAVA">Phase 3 study</a>.
Cassava Sciences shares dipped 85.6% to $3.82 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Centessa Pharmaceuticals PLC – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) shares tumbled 12% to $15.00 in pre-market trading after falling 6% on Friday. On Nov. 12, Centessa Pharmaceuticals reported a quarterly loss of 37 cents per share.</li>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) fell 11% to $40.60 in pre-market trading after the company announced its treatment arm of the RESILIENT SMA study did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care group.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 6.9% to $22.15 in pre-market trading. ZIM Integrated Shipping Services, last week, reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBIT and EBITDA guidance.</li>
<li>i3 Verticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) shares declined 6.6% to $22.11 in pre-market trading. The company, last week, posted downbeat quarterly results.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) fell 5.9% to $7.00 in pre-market trading.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined 4.9% to $24.00 in pre-market trading after gaining around 6% on Friday.</li>
<li>Logility Supply Chain Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) fell 4.4% to $9.31 in pre-market trading. Logility Supply Chain Solutions shares dipped 13% on Friday after the company reported worse-than-expected second-quarter revenue results and issued FY25 revenue guidance below estimates.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 4.3% to $6.90 in today's pre-market trading after jumping around 25% on Friday. Kingsoft Cloud, last week, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million</li>
</ul>
Now Read This: 
<a href="https://www.benzinga.com/24/11/42157664/zoom-video-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Zoom Video Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Pre-Market Outlook

Movers

BHVN

CDXC

CNTA

FTEL

IIIV

LGTY

SAVA

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

PLUR

Pluri Assesses Readiness For Mass Production Of PLX-R18 For Acute Radiation Syndrome

Social Media

Dr Disrespect To Provide Exclusive Content To Rumble Premium And Lead Rumble Gaming, Acting As An Advisor

Compass Point analyst Merrill Ross maintains Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Buy and lowers the price target from $15.75 to $14.75.

Compass Point Maintains Buy on Two Harbors Inv, Lowers Price Target to $14.75

New smart eyewear is the Company's first to use advanced TR90 plastic for improved adjustability and durability.
MIAMI, Nov. 25, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4310635-1&amp;h=4217338290&amp;u=https%3A%2F%2Flucyd.co%2F&amp;a=Innovative+Eyewear%2C+Inc.">Innovative Eyewear, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>, LUCYW))), the developer of ChatGPT-enabled smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, announced today that it has officially launched the Lucyd Lyte 2024 Edition, bringing several improvements to the Company's core product line. Key improvements over previous models include improved adjustability and durability, reduced weight, and upgraded lenses.&nbsp;

LUCY

Innovative Eyewear Launches Four New Lucyd Lyte Smart Glasses, The Lucyd, Nautica, Eddie Bauer And Reebok Brands With Enhanced Features

Buybacks

ERNA

Eterna Therapeutics Announces Stock Repurchase Program Of Up To $1M

Macro Economic Events

Econ #s

Economics

Chicago Fed National Activity For Oct. -0.40 Vs -0.20 Est.; -0.27 Prior

In the current session, the stock is trading at $59.89, after a 0.40% spike. Over the past month, Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) stock increased by 15.07%, and in the past year, by 64.19%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732541406_0.png" alt="Past Year Chart" />

<h3>Comparing Williams Companies P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Williams Companies has a better P/E ratio of 25.28 than the aggregate P/E ratio of 18.49 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that Williams Companies Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732541406_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Williams Companies

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Conmed Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>)</h3>
<ul>
<li>On Oct. 30, Conmed reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of 99 cents per share. &#8220;Our third quarter results were largely in line with our expectations, and we remain focused on getting fully back on offense,&#8221; commented Curt R. Hartman, CONMED&#8217;s Chair of the Board, President, and Chief Executive Officer. &#8220;I am particularly proud of how our teams responded to the disruption from hurricanes Helene and Milton, which temporarily impacted our employees and facilities in the Southeast as well as many of our customers.&#8221; The company's stock gained around 21% over the past month and has a <a href="https://www.benzinga.com/quote/CNMD">52-week high of $117.27</a>.</li>
<li>RSI Value: 70.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CNMD Price Action: Shares of Conmed gained 4.5% to close at $74.91 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Madrigal Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)</h3>
<ul>
<li>On Oct. 31, Madrigal Pharmaceuticals reported better-than-expected third-quarter financial results. Bill Sibold, Chief Executive Officer of Madrigal, stated, &#8220;Our U.S. launch of Rezdiffra is progressing exceptionally well driven by the outstanding execution of our team. Growing adoption by prescribers, broader payer coverage and an increasing number of patients on therapy each contributed to the strong performance. This early success highlights the critical need for effective treatments for moderate to advanced NASH/MASH, which is expected to become the leading cause of liver transplants in the U.S.&#8221; The company's stock gained around 65% over the past month and<a href="https://www.benzinga.com/quote/MDGL"> has a 52-week high</a> of $368.29.</li>
<li>RSI Value: 74.01</li>
<li>MDGL Price Action: Shares of Madrigal Pharmaceuticals gained 5.5% to close at $347.45 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Butterfly Network Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>)</h3>
<ul>
<li>On Nov. 1, Butterfly Network reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates. The company's stock gained around 78% over the past month and has a <a href="https://www.benzinga.com/quote/BFLY">52-week high</a> of $3.55.</li>
<li>RSI Value: 72.56</li>
<li>BFLY Price Action: Shares of Butterfly Network fell 1.4% to close at $3.24 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Short Ideas

BFLY

CNMD

MDGL

Top 3 Health Care Stocks That May Dip This Month

Lawrence E. Kurzius, Executive Chairman of the Board of McCormick &amp; Company, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>), a global leader in flavor, announced that he will end his eight years of service as Chairman on December 31, 2024.&nbsp; Mr. Kurzius will continue as a Board member for McCormick, where he was employed for 22 years.&nbsp; He will not stand for re-election at the Company's annual shareholder meeting in March 2025.&nbsp; Mr. Kurzius transitioned the Chief Executive Officer responsibilities to Brendan Foley in September 2023 and continued to serve as Executive Chairman since that time.
McCormick's Board of Directors has appointed Brendan Foley, the Company's President and Chief Executive Officer, to succeed Mr. Kurzius as Chairman, in addition to his current duties, effective January 1, 2025.

Management

McCormick & Company Announces Brendan Foley To Succeed Lawrence Kurzius As Chairman Of The Board, Effective January 1, 2025

Goldman Sachs analyst Robert Cox upgrades WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) from Neutral to Buy and announces $69 price target.

Upgrades

Goldman Sachs Upgrades WR Berkley to Buy, Announces $69 Price Target

Seaport Global analyst David Joyce reiterated a Hold rating on Fox (FOXA – Research Report) today. The company's shares closed yesterday at $43.00....

Seaport Global Sticks to Their Hold Rating for Fox (FOXA)

Macquarie analyst Tim Nollen has maintained their neutral stance on FOXA stock, giving a Hold rating today. Tim Nollen's rating is based on Fox's s...

Fox's Strong Q1 FY25 Performance Balanced by Caution in Media Landscape: Hold Rating Maintained

Macquarie raised the firm's price target on Fox Corp. (FOXA) to $39 from $35 and keeps a Neutral rating on the shares, citing a higher sum-of-the-p...

Fox Corp. price target raised to $39 from $35 at Macquarie

Stocks in Communication Services rise on investor optimism for sector under Trump's second term

Media giant and theme park operator Disney (DIS) is scheduled to report results of its fiscal fourth quarter before the market open on Thursday, No...

What Wall Street experts are saying about Disney ahead of earnings

Trump taps Sean Duffy, second Fox host, to be transportation secretary

Evercore ISI analyst Shweta Khajuria raised the firm's price target on Trade Desk (TTD) to $135 from $110 and keeps an Outperform rating on the sha...

Trade Desk price target raised to $135 from $110 at Evercore ISI

Fox Entertainment (FOXA) and Hulu (DIS) are staying in business together in a major way, with the two companies having struck a new multi-year cont...

Fox, Hulu extend streaming deal with $1.5B pact, Deadline reports

Fox: Underestimating The Post-Election Upswing

Fox, Hulu renew multi-platform streaming arrangement for +$1.5B - report

CHTR

CMCSA

FOXA

MTCH

NFLX

NWSA

PARA

PARAA

RSPC

TMUS

TTWO

Press Releases

OutKick Sees Q3 Growth in Multiplatform Views & Minutes

OutKick's Maintaining with Tyrus to Feature Interview with Former President Donald Trump

Entertainment

Fox Corporation Executives to Discuss First Quarter Fiscal 2025 Financial Results Via Webcast

FOX News Channel to Debut New Immersive Graphics Technology in Enhanced State-of-the-Art Studio During 2024 Election Coverage

FOX REPORTS FIRST QUARTER FISCAL 2025 REVENUES OF $3.56 BILLION, NET INCOME OF $832 MILLION, AND ADJUSTED EBITDA OF $1.05 BILLION

FOX News Media's 2024 Election Night Coverage Leads All Broadcast and Cable Networks With Over 13 Million Viewers

FOX News Channel Post-Election Performance Sets New Records and Beats Every Network With Nearly 8 Million Viewers During Harris Concession Speech

Sean Hannity to Host FOX Nation's Signature Patriot Awards Ceremony on December 5

FOX News Digital Overtakes CNN With Total Digital Multiplatform Unique Visitors in October

OutKick Delivers Massive Growth Month Over Month and Year Over Year in October 2024

Comments

Fox

Actualités

Dernières nouvelles pour Fox (NASDAQ:FOX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL